Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Takeda Pharmaceutical Co. Ltd.. (1/5/18). "Press Release: Takeda Announces Intention to Acquire TiGenix. Expands Takeda’s Late Stage Pipeline and Leadership in Gastroenterology". Osaka.

Organisations Organisation Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
  Organisation 2 TiGenix N.V. (Euronext + Nasdaq: TIG)
  Group Takeda (Group)
Products Product darvadstrocel (Cx601)
  Product 2 investment banking
Index term Index term TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share
Persons Person Plump, Andrew (Takeda 201610 CMO + CSO)
  Person 2 Bravo, Eduardo (Nordic Nanovector 201807– CEO before TiGenix + Cellerix + Sanofi-Aventis + SKB)

Record changed: 2019-06-09


Picture [iito] Made Without Love 650x80px

More documents for Takeda (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top